NCT06546280View on ClinicalTrials.gov

A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 26, 2024

Primary Completion Date

August 26, 2026

Study Completion Date

September 1, 2026

Conditions

Hepatocellular Carcinoma

Interventions

DRUG

Camrelizumab

Camrelizumab 200 mg will be administered by IV infusion on Day 1 of each 21-day cycle.

DRUG

Apatinib

Apatinib 250 mg will be taken orally once daily.

Trial Locations (1)

510220

Zhujiang Hospital of Southern Medical University, Guangzhou

All Listed Sponsors

lead

Zhujiang Hospital

OTHER

NCT06546280 - A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation | Biotech Hunter | Biotech Hunter